I-MAB (NAS:IMAB)
$ 1.055 -0.04 (-3.64%) Market Cap: 81.84 Mil Enterprise Value: -118.19 Mil PE Ratio: 0 PB Ratio: 0.35 GF Score: 35/100

I-Mab at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 11, 2022 / 09:30PM GMT
Release Date Price: $39.02 (-2.18%)
Lingling Chen

Hello, everyone. Welcome to the 2022 JPMorgan Global Healthcare Conference. I'm Lingling Chen from China healthcare investment banking team. And today, we are very honored without Dr. Jingwu Zang from I-Mab biopharma to present at our conference. I-Mab is a biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics. Since its establishment, I-Mab has experienced tremendous growth and has developed an innovative pipeline of over 10 clinical stage assets. The company has also been listed on the NASDAQ since January 2020. Our speaker today, Dr. Jingwu Zang is the Founder and Chairman of the company with over 30 years of experience in the academia and industry.

Now I'll pass the stage on to Dr. Zang for the presentation. Thank you.

Jingwu Zhang Zang
I-Mab - Founder, Chairman & Acting CEO

Hi, I'm Jingwu Zang, Founder, Chairman and the Acting CEO of I-Mab. First of all, I'd like to thank you all for joining this virtual meeting today. This is a great opportunity for me to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot